What are the benefits of leukoreduction in blood products?

Master the CAMLPR Transfusion Test with interactive questions and detailed explanations. Boost your knowledge and ensure you're exam-ready with comprehensive study resources!

Multiple Choice

What are the benefits of leukoreduction in blood products?

Leukoreduction works by removing most donor white blood cells from blood products before transfusion, which lowers several reaction and infection risks that can follow a transfusion. First, febrile nonhemolytic transfusion reactions are largely driven by cytokines released by donor leukocytes and by recipient reactions to those leukocytes. By removing those white cells, the amount of triggering material is reduced, so fevers and related symptoms are less likely to occur. Second, exposure to donor leukocyte antigens can lead to alloimmunization against HLA antigens. Fewer donor leukocytes mean fewer opportunities for the recipient’s immune system to encounter those HLA antigens, decreasing the chance of sensitization that can complicate future transfusions or organ or stem cell transplants. Third, leukocytes can carry certain infections, most notably CMV, and leukoreduction lowers the risk of transmitting these leukocyte-associated infections to recipients, especially those who are immunocompromised or CMV-seronegative. The other statements contradict what leukoreduction actually achieves: it does not increase infection risk, it does impact transfusion reactions, and its benefit is not limited to reducing bacterial contamination alone.

Leukoreduction works by removing most donor white blood cells from blood products before transfusion, which lowers several reaction and infection risks that can follow a transfusion.

First, febrile nonhemolytic transfusion reactions are largely driven by cytokines released by donor leukocytes and by recipient reactions to those leukocytes. By removing those white cells, the amount of triggering material is reduced, so fevers and related symptoms are less likely to occur.

Second, exposure to donor leukocyte antigens can lead to alloimmunization against HLA antigens. Fewer donor leukocytes mean fewer opportunities for the recipient’s immune system to encounter those HLA antigens, decreasing the chance of sensitization that can complicate future transfusions or organ or stem cell transplants.

Third, leukocytes can carry certain infections, most notably CMV, and leukoreduction lowers the risk of transmitting these leukocyte-associated infections to recipients, especially those who are immunocompromised or CMV-seronegative.

The other statements contradict what leukoreduction actually achieves: it does not increase infection risk, it does impact transfusion reactions, and its benefit is not limited to reducing bacterial contamination alone.

More practice questions